Biotech Trial Pressure And Wins
Kilder
- Endpoints: An uncertain future for Aurora, the first startup dedicated to custom CRISPR therapies
- Endpoints: Akeso, Summit hail ivonescimab’s biliary tract cancer win in China-only Phase 3 trial - Endpoints News
- Endpoints: Amgen, medical centers diverge on potential conflicts in FDA pilot to speed early drug trials - Endpoints News
- Endpoints: An uncertain future for Aurora, the first startup dedicated to custom CRISPR therapies
- Endpoints: Akeso, Summit hail ivonescimab’s biliary tract cancer win in China-only Phase 3 trial - Endpoints News
- Endpoints: Amgen, medical centers diverge on potential conflicts in FDA pilot to speed early drug trials - Endpoints News
- Endpoints: An uncertain future for Aurora, the first startup dedicated to custom CRISPR therapies
- Endpoints: Akeso, Summit hail ivonescimab’s biliary tract cancer win in China-only Phase 3 trial - Endpoints News
- Endpoints: Amgen, medical centers diverge on potential conflicts in FDA pilot to speed early drug trials - Endpoints News
- Endpoints: Haisco grants license to Sentivera; ViiV's HIV treatment OK'd for newborns
- Endpoints: Haisco grants license to Sentivera; ViiV's HIV treatment OK'd for newborns
- STAT: STAT+: AI biotech Insitro’s Daphne Koller on how to speed up clinical trials
- Endpoints: MassBio report details challenges spanning China, NIH
- STAT: STAT+: Key data on a new class of cardio drugs are coming
- Ua: Key data on a new class of cardiovascular drugs expected soon - UA.NEWS
- STAT: On the fence about a statin? In borderline cases, calcium scans could be a tiebreaker - STAT
- Endpoints: Spyre drops rheumatoid arthritis hopes for anti-TL1A drug after modest Phase 2 data
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.